Keywords
Acknowledgements
References
-
1.
Al Ajlouni M, Abujbara M, Batieha A, Ajlouni K. Prevalence of lipohypertrophy and associated risk factors in insulin-treated patients with type 2 diabetes mellitus. Int J Endocrinol Metab. 2015;13(2). eeeee20776. [PubMed ID: 25926852]. https://doi.org/10.5812/ijem.20776.
-
2.
Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39(5):445-53. [PubMed ID: 23886784]. https://doi.org/10.1016/j.diabet.2013.05.006.
-
3.
Gentile S, Agrusta M, Guarino G, Carbone L, Cavallaro V, Carucci I, et al. Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol. 2011;48(2):121-5. [PubMed ID: 20091324]. https://doi.org/10.1007/s00592-009-0172-x.
-
4.
Grassi G, Scuntero P, Trepiccioni R, Marubbi F, Strauss KW. Optimizing insulin injection technique and its effect on blood glucose control. J Clin Translational Endocrinol. 2014;1(4):145-50. https://doi.org/10.1016/j.jcte.2014.07.006.
-
5.
Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4(10):661-7. [PubMed ID: 14507228].
-
6.
Holstein A, Stege H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Saf. 2010;9(2):225-31. [PubMed ID: 20001763]. https://doi.org/10.1517/14740330903496402.